AIM
BSTC

Acrospire Investment Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Acrospire Investment Management’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,608
Closed -$80K – 1770
2017
Q2 		$80K Sell
1,608
-202
-11% -$10.6K 0.08% 403
2017
Q1 		$99K Sell
1,810
-1,570
-46% -$83.1K 0.08% 327
2016
Q4 		$188K Sell
3,380
-1,076
-24% -$51.7K 0.08% 402
2016
Q3 		$204K Sell
4,456
-759
-15% -$30.5K 0.14% 156
2016
Q2 		$208K Sell
5,215
-3,427
-40% -$126K 0.15% 59
2016
Q1 		$301K Buy
+8,642
New +$317K 0.21% 28

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Acrospire Investment Management's BSTC Position: Q3 2017 in Review

Acrospire Investment Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2017, closing a stake of 1,608 shares — an estimated $80K sold.

Acrospire Investment Management first reported a position in BSTC in Q1 2016 and held it in 6 quarters. The position peaked at $301K in Q1 2016. 87 funds tracked by Wall St. Rank hold BSTC as of Q3 2017.

  • Acrospire Investment Management reported no remaining BioSpecifics Technologies Corp. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,608 BioSpecifics Technologies Corp. shares in Q3 2017, an estimated $80K.
  • Acrospire Investment Management first reported a position in BioSpecifics Technologies Corp. in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's BioSpecifics Technologies Corp. position peaked at $301K in Q1 2016.
  • 87 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.